Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
AdAlta Ltd. ( (AU:1AD) ) has provided an announcement.
AdAlta Ltd. announced the cessation of 4,929,060 securities due to the expiry of options or other convertible securities without exercise or conversion as of November 26, 2025. This cessation of securities may impact the company’s capital structure and could have implications for its financial strategy and stakeholder interests.
The most recent analyst rating on (AU:1AD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Ltd. operates in the biotechnology industry, focusing on the development of innovative therapeutic products. The company is known for its proprietary i-body technology, which is used in the development of new drugs targeting a range of diseases.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.62M
For detailed information about 1AD stock, go to TipRanks’ Stock Analysis page.